66
Participants
Start Date
April 29, 2008
Primary Completion Date
March 16, 2010
Study Completion Date
June 11, 2012
PF-00299804
PF-00299804 orally at 45 mg daily, on continuous schedule
PF-00299804
PF-00299804 orally at 45 mg daily, on continuous schedule
CCR, National Cancer Institute, Bethesda
Grady Health Systems, Atlanta
Emery University Hospital Midtown, Atlanta
Emory Clinic, Atlanta
Emory University Hospital, Atlanta
Winship Cancer Institute, Atlanta
Karmanos Cancer Institute/Wayne State University, Detroit
Lawrence and Idell Weisberg Cancer Treatment Center, Farmington Hills
Rocky Mountain Lions Eye Institute, Aurora
University of Colorado Hospital, Anschutz Cancer Pavilion, Aurora
University of Colorado Hospital, Anschutz Inpatient Pavilion, Aurora
University of Colorado Hospital, Aurora
City of Hope, Duarte
City of Hope South Pasadena Cancer Center, South Pasadena
City of Hope Medical Group, Pasadena
Massachusetts General Hospital, Boston
Brigham and Women's Hospital, Boston
Dana Farber Cancer Institute, Boston
Beth Israel Deaconess Medical Center, Boston
Lead Sponsor
Pfizer
INDUSTRY